PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma.
Adding a common arthritis medication to immunotherapy restores immune cell function and overcomes resistance in mouse lung cancer, ready for clinical testing.
The authors established an orthotopic bioluminescence-tracked LLC1 model capturing heterogeneous anti-PD-1 responses including relapse, then used genome-wide CRISPR loss-of-function screening to identify Ptgs2 as the dominant acquired resistance driver. Mechanistic validation showed PGE2 progressively increases in resistant tumors and suppresses NK-cell cytotoxicity through cAMP elevation; COX-2 inhibitor celecoxib restored NK function and overcame resistance—a testable combination therapy immediately actionable in clinical trial design.
What the study was
- Study design
- mechanistic_preclinical
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
In vivo CRISPR screen for acquired checkpoint resistance is methodologically landmark; PGE2/EP2/EP4/NK axis is novel and actionable via existing approved drug (celecoxib); JITC publication with CC BY-NC open access; directly applicable to large NSCLC patient population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.